BioScale Inc., an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles (AMMP™) assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry. The data presented in the article show clearly that the BioScale platform offers a robust and rapid method for measuring recombinant standards or endogenously derived proteins from both tissue culture and mouse xenograft tumor lysates.
“We have hit another milestone for BioScale with publication of the Millennium pharmacodynamic biomarker results in Analytical Biochemistry”
Dr. Zhong-Hua Yan, Senior Scientist at Millennium Pharmaceuticals: The Takeda Oncology Company, was the lead author of the article. Dr. Michael Bembenek, Associate Director, Lead Discovery, oversaw the comparative analyses that were performed in the study. For this research, pharmacodynamic biomarkers for both proteasome and phosphoinositol 3-kinase inhibition were used. The two pathway biomarkers were compared with either AlphaScreen or LI-COR Western blot assays. In addition to being a robust and rapid method for measuring recombinant standards or endogenously derived proteins from both tissue culture and mouse xenograft tumor lysates, BioScale's ViBE Protein Analysis Workstation showed that the sensitivity obtained with the BioScale platform compares favorably with LI-COR Western blot and AlphaScreen technologies. Furthermore, the use of the ViBE eliminated the labor-intensive effort of Western blot analysis and is devoid of the optical and other endogenous interfering substances derived from lysates of xenograft tumors typically observed with AlphaScreen.
"We have hit another milestone for BioScale with publication of the Millennium pharmacodynamic biomarker results in Analytical Biochemistry," said Brett Masters, BioScale's Chief Technology Officer. "We look forward to continued execution of our commercialization plans for the ViBE and believe the simplicity and flexibility of the platform will provide scientists the ability to perform a wide range of protein analysis, not only with more sensitive, reproducible data, but with the power to work in complex samples more efficiently than ever before."